Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Principal Investigator
Name
Katherine McGlynn
Degrees
Ph.D.
Institution
National Cancer Institute
Position Title
Senior Investigator
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-631
Initial CDAS Request Approval
Jun 2, 2020
Title
Genome wide association study (GWAS) of cholangiocarcinoma (CCA)
Summary
The main objective of this study is to identify genetic risk variants associated with CCA in a large, well-powered GWAS. It is anticipated that successful completion of this study may eventually lead to new insights about etiology. In addition, the GWAS results may provide new insights into the pathophysiology of CCA and reveal the contributions of unsuspected pathogenic pathways to CCA development. Overall CCA will be examined, as will the subtypes intrahepatic and extrahepatic CCA and primary sclerosing cholangitis associated (PSC)-CCA. Cases will be drawn from populations in North America and Europe. Controls will be drawn from the PLCO population. All genotyping will be done at CGR using the GSA chip.
Aims

1) Examine associations between SNPs and CCA.
2) Examine associations by sex.
3) Examine associations between SNPs and intrahepatic and extrahepatic CCA separately.
4) Examine associations between SNPs and PSC-associated CCA.

Collaborators

Lewis R. Roberts, Mayo Clinic, Rochester, MN
Christopher I. Amos, Baylor College of Medicine, Houston, TX